YONKERS, N.Y., July 30 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced that Paul R. Bishop has been
named to the Company's Board of Directors.  Mr. Bishop is Chairman and CEO of
H-P Products, Inc. of Louisville, Ohio -- a leading manufacturer of household
central vacuum systems and fabricated tubing systems and metal components for
various major industries, including the automotive industry.
    In addition to his current position with H-P Products, Mr. Bishop is a
member of the Board of Directors for the Hawk Group of Companies, a publicly
traded manufacturer of specialized components used in industrial, commercial
and aerospace applications.
    "Paul brings extensive leadership and entrepreneurial experience in both
publicly traded and private corporations to our Company, as well as an
extensive network of executive talent and potential capital investors and
advisors as a result of his leadership participation in such organizations as
the Young Presidents' Organization (YPO)," said Eli Wilner, Chairman of the
Board in announcing Bishop's appointment.  "His appointment continues to
expand the breadth of experience represented by the members of our Board."
    In addition to holding numerous positions with the YPO including
International President, Mr. Bishop is a member of the Chief Executives'
Organization and World Presidents' Organization and has served on the Board of
Directors for both organizations.  Mr. Bishop is a member of the Ohio and
American Bar Associations.
    "As the clinical trials on Product R progress, we are hopeful that Paul's
relationships with national and international business leaders will be helpful
in attracting additional investment capital to the Company," added Shalom Z.
Hirschman, M.D., President and Chief Executive Officer.  Other members of the
Board include Chairman Eli Wilner (CEO, Eli Wilner and Company), Shalom Z.
Hirschman, M.D. (President and CEO, Advanced Viral Research Corp.); James F.
Dicke II (President and CEO, Crown Equipment Corporation); David A. Seligman,
Esq. (former Associate General Counsel, Hoffmann-La Roche, Inc.); Nancy J. Van
Sant, Esq. (a Director with Sacher, Zelman, Van Sant, Paul, Beiley, Hartman &
Waldman); and Roy S. Walzer (CEO Litchfield Partners and Litchfield Partners
I).
    ADVR's Product R represents a biopolymer chemistry that possesses novel
immunomodulator activity.  This peptide-nucleic acid, which to date has shown
no indication of human toxicity, appears to stimulate the proinflammatory
responses required to combat viral infections such as AIDS and human papilloma
virus and to dampen aberrant autoimmune-type inflammatory responses, such as
occur in patients with rheumatoid arthritis.
    Therefore, Product R has been termed a "switch type" immunomodulator.
Product R is also being studied for the promise shown in its ability to
mitigate the toxic side effects of other drugs, including those used to treat
HIV infection and chemotherapeutic drugs employed in the treatment of cancers,
and the body wasting (cachexia) that is a frequent complication of cancers and
AIDS.

    Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm dedicated to improving patients' lives by researching,
developing and bringing to market new and effective therapies for viral and
other diseases.

    Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company.  Product R is not
approved by the U.S. Food and Drug Administration or any comparable agencies
of any other countries.  There is no assurance that the Company will be able
to secure the financing necessary to continue and/or complete the clinical
trials of Product R or satisfy certain other conditions relating to clinical
trials including obtaining adequate insurance on terms acceptable to the
Company.  The Company undertakes no obligation to update or revise the
information contained in this announcement whether as a result of new
information, future events or circumstances or otherwise.

     Contact Information: Mayr Communications, 1-877-777-6010, or
                          mayrcomm@att.net

Link to this page: